Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
(S)-Roscovitine
140
CHF
CHF 140.00
In stock
AG-MR-C0002-M0055 mgCHF 140.00
AG-MR-C0002-M02525 mgCHF 560.00
| Product Details | |
|---|---|
| Synonyms | 6-Benzylamino-2-(S)-[(1-ethyl)-2-hydroxyethylamino]-9-isopropylpurine |
| Product Type | Chemical |
| Properties | |
| Formula |
C19H26N6O |
| MW | 354.5 |
| CAS | 186692-45-5 |
| Purity Chemicals | ≥99% (NMR) |
| Appearance | White to off-white solid. |
| Solubility | Soluble in DMSO, ethanol or methanol. |
| Reconstitution | Stock solutions can be made up to 10mM in DMSO. |
| Identity | Determined by 1H-NMR. |
| InChi Key | BTIHMVBBUGXLCJ-HNNXBMFYSA-N |
| Smiles | CC[C@@H](CO)NC1=NC2=C(N=CN2C(C)C)C(NCC2=CC=CC=C2)=N1 |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice |
After standard reconstitution, prepare aliquots and store at -20°C. Protect from light and moisture. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
- (S)-enantiomer of (R)-roscovitine (Prod. No. MR-C0001).
- Potent selective cyclin-dependent kinase 1 (CDK1) inhibitor.
- Potential neuroprotectant for stroke. Crosses the blood brain barrier. Inhibits CDK5, consequently blocking hypoxia-induced apoptosis in neurons.
- Potential anti-inflammatory compound.
- Potential antidiabetic compound.
Product References
- Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5: L. Meijer, et al.; Eur. J. Biochem. 243, 527 (1997)
- Maintenance of meiotic arrest in bovine oocytes using the S-enantiomer of roscovitine: effects on maturation, fertilization and subsequent embryo development in vitro: P. Coy, et al.; Reprod. 129, 19 (2005)
- Delayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke models: B. Menn, et al.; PLoS One 5, e12117 (2010)
Related Products
